Results 191 to 200 of about 26,813 (237)

Targeting Multidrug Resistance in Cancer: Impact of Retinoids, Rexinoids, and Carotenoids on ABC Transporters. [PDF]

Int J Mol Sci
Čižmáriková M, Háziková V, Michalková R, Franko O, Lešková B, Homolya AD, Gabzdilová J, Takáč P.   +7 more
europepmc   +1 more source

<i>BIRC5</i> Promoter-Driven Nanodrugs Suppress BIRC5-Positive Cancers Independent of ABCB1 Status and IDO1 Expression. [PDF]

Int J Nanomedicine
Chang YC, Huang WL, Su WC, Leung E, Cheng FY, Cheung CHA.   +5 more
europepmc   +1 more source

Network pharmacology and molecular docking reveal mechanisms of amiodarone-induced pulmonary fibrosis. [PDF]

Sci Rep
Li H, Di R, Kong D.
europepmc   +1 more source

Genetics of ABCB1 in Cancer

Cancers, 2023
ABCB1, also known as MDR1, is a gene that encodes P-glycoprotein (P-gp), a membrane-associated ATP-dependent transporter. P-gp is widely expressed in many healthy tissues—in the gastrointestinal tract, liver, kidney, and at the blood–brain barrier. P-gp works to pump xenobiotics such as toxins and drugs out of cells.
Katie T Skinner, Andrew L Hong, Hong Andrew L   +2 more
exaly   +4 more sources

Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates

International Journal of Molecular Sciences, 2019
ABCB1 is one of the major drug efflux transporters that is known to cause multidrug resistance (MDR) in cancer patients receiving chemotherapy for the treatment of solid tumors and hematological malignancies.
Pranav Gupta, Sabesan Yoganathan, Zhe-Sheng Chen   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Euphorbia factor L1 reverses ABCB1‐mediated multidrug resistance involving interaction with ABCB1 independent of ABCB1 downregualtion

Journal of Cellular Biochemistry, 2011
AbstractEuphorbia factor L1 (EFL1) belongs to diterpenoids of genus Euphorbia. In this article, its reversal activity against ABCB1‐mediated MDR in KBv200 and MCF‐7/adr cells was reported. However, EFL1 did not alter the sensitivity of KB and MCF‐7 cells to chemotherapeutic agents. Meanwhile, EFL1 significantly increased accumulation of doxorubicin and
Jian-ye, Zhang, Yan-jun, Mi, Shu-peng, Chen, Fang, Wang, Yong-ju, Liang, Li-sheng, Zheng, Cheng-jun, Shi, Li-yang, Tao, Li-ming, Chen, Hu-biao, Chen, Li-wu, Fu   +10 more
openaire   +2 more sources

ABCB1 in children's brain tumours

Biochemical Society Transactions, 2015
Tumours of the central nervous system are the most common solid tumour, accounting for a quarter of the 1500 cases of childhood cancer diagnosed each year in the U.K. They are the most common cause of cancer-related death in children. Treatment consists of surgery followed by adjuvant chemotherapy and/or radiotherapy.
Beth, Coyle, Maya, Kessler, Durgagauri H, Sabnis, Ian D, Kerr   +3 more
openaire   +2 more sources

ABCB1 Genotyping in the Treatment of Depression

Pharmacogenomics, 2016
P-glycoprotein (P-gp), the gene product of ABCB1, is a drug transporter at the blood-brain barrier and could be a limiting factor for entrance of antidepressants into the brain, the target site of antidepressant action. Animal studies showed that brain concentrations of many antidepressants depend on P-gp.
Brückl, T., Uhr, M.
openaire   +3 more sources

Estimation of ABCB1 concentration in plasma membrane

Journal of Cellular Biochemistry, 2019
Abstract The interaction between ABCB1 transporter and its substrates takes place in cell membranes but the available data precludes quantitative analysis of the interaction between transporter and substrate molecules. Further, the amount of transporter is usually expressed as a number of ABCB1 molecules per cell.
Petr Mlejnek, Petr Kosztyu, Petr Dolezel, Yasuhisa Kimura, Katerina Cizkova, Eliska Ruzickova   +5 more
openaire   +2 more sources